$CRDF

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (1d)

+0.4%

Win rate (1d)

50% (2 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 2m ago

$CRDFr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/SeniorVicePrez · 45d ago1 prior · awaiting results

Long CRDF

Settlement yesterday is just the beginning for CRDF

Cardiff Oncology's settlement with Nerviano removes litigation overhang and clears path for Phase 3 trial of onvansertib in RAS-mutated colorectal cancer. Strong insider buying, FDA meeting completion, analyst upgrade to $9 PT, and robust cash position ($44.5M+) support significant upside from current levels.

At post $1.34Now $0.89-33.9% since posted2m ago

1d+0.7%

3d+2.2%

1w-0.7%

1m-27.6%

3m—

6m—

1y—

original post →

$CRDFr/pennystocksBullishbullish

u/SeniorVicePrez · 50d ago1 prior · awaiting results

A big insider purchase got me into CRDF recently

Micro-cap biotech with phase 3 trial catalyst (Q1 2027) targeting RAS-mutated mCRC using onvansertib, which showed strong phase 2 results versus standard-of-care. Recent $1M insider purchase and resolution of patent dispute with NMS could unlock upside toward analyst price targets of $4.18-$7.50.

At post $1.21Now $0.89-26.7% since posted2m ago

1d0.0%

3d0.0%

1w+7.4%

1m-10.7%

3m—

6m—

1y—

original post →

End of results.